First Time Loading...
Y

Yifan Pharmaceutical Co Ltd
SZSE:002019

Watchlist Manager
Yifan Pharmaceutical Co Ltd
SZSE:002019
Watchlist
Price: 13.89 CNY -0.14% Market Closed
Updated: May 21, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

11.5B
-7%
Assets
Growth Rates:
1 Year
-8%
3 Years
-1%
5 Years
+18%
7 Years
+65%
10 Years
+1 609%
3.2B
-4%
Liabilities
Growth Rates:
1 Year
-14%
3 Years
+1%
5 Years
+2%
7 Years
-7%
10 Years
+1 023%
8.3B
-8%
Equity
Growth Rates:
1 Year
-6%
3 Years
-2%
5 Years
+25%
7 Years
+135%
10 Years
+2 044%

Balance Sheet Decomposition
Yifan Pharmaceutical Co Ltd

11.5B
Assets
3.2B
Liabilities
11.5B
Assets
3.2B
Liabilities
Current Assets 3.3B
Cash & Short-Term Investments 647.8m
Receivables 1.4B
Other Current Assets 1.2B
Non-Current Assets 8.2B
Long-Term Investments 717m
PP&E 1.9B
Intangibles 5.3B
Other Non-Current Assets 308.8m
Current Liabilities 2.2B
Accounts Payable 431.4m
Accrued Liabilities 203.2m
Short-Term Debt 609.1m
Other Current Liabilities 943.7m
Non-Current Liabilities 1B
Long-Term Debt 878.8m
Other Non-Current Liabilities 157.8m

Balance Sheet
Yifan Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
277
332
729
1 281
1 185
922
871
863
712
573
Cash
0
0
0
0
0
0
0
178
712
573
Cash Equivalents
277
332
729
1 281
1 185
922
871
685
0
0
Short-Term Investments
0
0
0
0
10
39
67
0
96
75
Total Receivables
522
631
954
1 132
1 153
1 212
1 358
1 380
1 422
1 392
Accounts Receivables
432
448
657
888
893
945
1 005
1 077
1 181
1 111
Other Receivables
90
183
297
244
260
267
353
302
241
281
Inventory
283
368
376
392
478
598
584
664
831
929
Other Current Assets
141
187
351
849
869
749
627
679
630
283
Total Current Assets
1 224
1 519
2 411
3 654
3 695
3 520
3 506
3 585
3 690
3 251
PP&E Net
673
839
820
910
1 104
1 289
1 491
1 793
1 742
1 880
PP&E Gross
673
839
820
910
1 104
1 289
1 491
1 793
1 742
1 880
Accumulated Depreciation
518
574
588
690
860
935
1 009
1 101
1 207
1 347
Intangible Assets
144
232
1 212
1 467
2 019
2 584
2 869
3 091
3 299
2 606
Goodwill
1 243
1 819
2 395
2 413
2 645
2 728
2 750
2 738
2 738
2 737
Note Receivable
0
0
0
0
0
0
0
0
2
1
Long-Term Investments
0
3
37
76
69
731
689
662
735
717
Other Long-Term Assets
51
135
109
248
243
214
333
296
338
307
Other Assets
1 243
1 819
2 395
2 413
2 645
2 728
2 750
2 738
2 738
2 737
Total Assets
3 335
N/A
4 547
+36%
6 984
+54%
8 768
+26%
9 775
+11%
11 066
+13%
11 637
+5%
12 165
+5%
12 544
+3%
11 500
-8%
Liabilities
Accounts Payable
162
175
237
220
363
399
372
351
288
431
Accrued Liabilities
46
55
91
109
99
103
116
156
236
203
Short-Term Debt
431
888
1 396
785
1 359
1 805
1 202
1 020
674
609
Current Portion of Long-Term Debt
2
0
120
136
98
42
18
434
572
507
Other Current Liabilities
117
311
724
337
477
535
420
341
429
436
Total Current Liabilities
757
1 429
2 568
1 587
2 396
2 883
2 129
2 302
2 199
2 187
Long-Term Debt
0
30
180
124
32
85
449
820
931
879
Deferred Income Tax
17
31
193
190
204
212
225
148
141
55
Minority Interest
1
22
376
314
264
322
290
239
335
21
Other Liabilities
18
177
141
85
255
64
104
120
126
124
Total Liabilities
791
N/A
1 689
+114%
3 459
+105%
2 299
-34%
3 151
+37%
3 566
+13%
3 197
-10%
3 630
+14%
3 732
+3%
3 224
-14%
Equity
Common Stock
261
261
921
1 027
1 027
1 057
1 055
1 054
1 046
1 046
Retained Earnings
457
774
1 438
2 638
2 900
3 690
4 542
4 754
4 950
4 402
Additional Paid In Capital
1 827
1 823
1 163
2 803
2 689
2 953
3 041
3 048
2 993
2 993
Treasury Stock
0
0
0
0
0
199
127
187
121
159
Other Equity
0
0
2
0
8
1
72
134
57
6
Total Equity
2 544
N/A
2 858
+12%
3 525
+23%
6 468
+83%
6 624
+2%
7 500
+13%
8 440
+13%
8 535
+1%
8 811
+3%
8 276
-6%
Total Liabilities & Equity
3 335
N/A
4 547
+36%
6 984
+54%
8 768
+26%
9 775
+11%
11 066
+13%
11 637
+5%
12 165
+5%
12 544
+3%
11 500
-8%
Shares Outstanding
Common Shares Outstanding
1 101
1 101
1 101
1 207
1 207
1 211
1 221
1 197
1 197
1 194

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.